Stabilization and delivery approaches for protein and peptide pharmaceuticals: An extensive review of patents

Recent Patents on Biotechnology

Volumn 7, Issue 1, 2013, Pages 28-46

  Swain, Suryakanta ^a   Mondal, Debanik ^a   Beg, Sarwar ^a   Patra, Chinam Niranjan ^a   Dinda, Subas Chandra ^b   Sruti, Jammula ^a   Rao, Muddana Eswara Bhanoji ^a  

^a Roland Institute of Pharmaceutical Sciences   (India)

^b BERHAMPUR UNIVERSITY   (India)

Author keywords

Degradation pathways; Delivery approaches; Patents; Stabilization

Indexed keywords

BIOSYNTHESIS; CONTROLLED DRUG DELIVERY; PATENTS AND INVENTIONS; TARGETED DRUG DELIVERY;

BIOMACROMOLECULE; BUILDING BLOCKES; DEGRADATION PATHWAYS; DELIVERY APPROACH; DRUG-DELIVERY SYSTEMS; HUMAN BODIES; PATENT; PATHOGENIC ORGANISMS; PEPTIDE DRUGS; PROTEIN DRUGS;

PEPTIDES;

ALPHA INTERFERON; ARGIPRESSIN[DEGLYCINAMIDE]; ASC 710; BCG VACCINE; CALCITONIN DERIVATIVE; CRYOPROTECTIVE AGENT; DORNASE ALFA; DRUG ADDITIVE; INSULIN; LEUPRORELIN; LIPOSOME; METAL CHELATE; MICROSPHERE; NAFARELIN; NANOPARTICLE; OSMOLYTE; OSMOTIC AGENT; PROTEINASE INHIBITOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADSORPTION KINETICS; CONCENTRATION (PARAMETERS); CONTROLLED RELEASE FORMULATION; DEAMINATION; DISULFIDE BOND; DRUG ABSORPTION; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG IMPLANT; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; GELATION; HUMAN; LIPOSOMAL DELIVERY; NONHUMAN; PAGET BONE DISEASE; PATENT; PH; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN DENATURATION; PROTEIN METABOLISM; PROTEIN STABILITY; REVIEW; SOLVENT EFFECT; STORAGE TEMPERATURE;

AVES;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HUMANS; PATENTS AS TOPIC; PEPTIDES; PROTEIN STABILITY; PROTEINS;

EID: 84881024301     PISSN: 18722083     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872208311307010004     Document Type: Review

References (132)

1. Bahl A, Bahal BS. Advanced organic chemistry. 1st ed. New Delhi: S. Chand & Company ltd 2010.
2. Avis KE. In: Lieberman HA, Lachman L, Eds. Pharmaceutical dosage forms: Parenteral medications. New York: Marcel Dekker 1996: pp.283, 295.
3. Chou PY, Fashman GD. Emperical prediction of protein conformation. Ann Rev Biochem 1978; 47: 251-76.
4. Sislbart LK, Karen DF. Reduction of intestinal carcinogen absorption by carcinogen-specific secretory immunity. Science 1989; 243: 1462-4.
5. Reddy RK, Banga AK. Stabilize a number of proteins against aggregation. Pharm Times 1993; 59: 93.
6. Volkin DB, Middangh CR, Eds. Chemical and physical pathway of protein degradation. New York: Plenum Press 1992: 215-6.
7. Israelachvili JN. Intermolicular and surface forces. 2nd ed. California: Accademic Press 1992
8. Schmid RD. Stabilized soluble enzymes. Adv Biochem Eng 1979; 12: 41.
9. Labuza TP, Saltmarch M. Water activity: Influence on food quality. New York: Academic Press 1981.
10. Li S, Patopoff TW, Overcashier D. Effect of reducing sugar on the chemical stability of human relaxin in the lyophilized state. J Pharm Sci 1996; 85: 873.
11. Holdan R, Pain RH. Tumour necrosis factor is in equilibrium with a trimeric molten globule at low pH. Febs Lett 1996; 343: 256-60.
12. Schwendeman SP, Castantino HR, Gupta RK. Stabilization of tetanus and diphtheria toxoids antigen against moisture-induced aggregation. Proc Natl Acad Sci 1995; 92: 11234-38.
13. Cannors KA, Amidon GL, Stella VJ. Chemical stability of pharmaceuticals. 2nd ed. New York: Wiley & Sons 1986.
14. Smith RJ, Webb ML. Analysis of Drug Impurities. 2nd ed. Oxford, UK: Blackwell 2007.
15. Azuaga AI, Dobson CM, Mateo PL. Unfolding and aggregation during the thermal denaturation of streptokinase. Eur J Biochem 2002; 269: 4121.
16. Carpenter JF, Pikal M, Chang BS. Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res 1997; 14: 969-75.
17. Jordan GM, Yashioka S, Terao T. Albumin aggregates: hydrodynamic shape and physico-chemical properties. Biotchhnol Bioeng 1991; 31: 177.
18. Eichner K, Ciner-Daruk M. Water activity: influence on food quality. Oxford: Academic Press 1996: pp. 567.
19. Lea CH, Hanman RS. Gastrointestinal tract infection. Biochem Biophys Act 1949; 3: 313.
20. Schwartz HM, Lea CH. The reaction between proteins and reducing sugars in the dry state: relative reactivity of the alpha and epsilon- amino groups of insulin. J Biochem 1952; 50: 713-16.
21. Volkin DB, Middaugh CR. Chemical & physical pathway of protein denaturation. 3rd ed. New York: Plenum Press 1992.
22. Charman SA, Mason KL, Charman WN. Techniques for assessing the effects of pharmaceutical excipients on the aggregation of procaine growth hormone. Pharm Res 1993; 10: 954-62.
23. Yamamoto K, Hayashi S, Yasui T. Hydrostatic pressure-induced aggregation of myosin molecule in 0.5 M KCl at pH-6.0. Biosci Biotechnol Biochem 1993; 57: 383-5.
24. Pearlman R, Qeswein JQ. Human growth hormon formulation. US596885, 1992.
25. Person KM, Gekas V. Factors influencing aggregation of macromolecules in solution. Process Biochem 1994; 29: 89-98.
26. Pekar AH, Frank BH. Conformations of proinsulin: comprision of insulin and proinsulin self assotiation at neutral pH. Biochem 1972; 11: 4013-16.
27. Philo JS, Arakawa T. Mechanism of protein aggregation. Current Pharm Biotechnol 2009; 10: 348-51.
28. Raso SW, Able J, Barnes JM. Aggregation of granulocyte-colony stimulating factors in vitro involves a conformationally altered monomeric state. Protein Sci 2005; 14: 2246-57.
29. Kendrick BS, Carpenter JF, Cleland JL. A transient expension of the native state precedes aggregation of recombinant human interferon- γ. Proc Natl Acad Sci 1998; 95: 14142-6.
30. Hermeling S, Schellekens H, Mass C. Antibody response to aggregated human interferon alpha2b in wild type and transgenic immunotolerant mice depends on type and level of aggregation. J Pharm Sci 2006; 95: 1084-96.
31. Chi EY, Krishnan S, Kendrick BS. Heterogenous nucleation controlled particulate formation of recombinant human plateletactivating factor acetylhydrolase in pharmaceutical formulation. J Pharm Sci 2005; 94: 256-74.
32. Tyagi AK, Randolph TW, Dong A. IgG particle formation during filling pump operation: a case study of heterogeneous nucleation on stainless steel nanoparticles. J Pharm Sci 2008; 93: 1398-1402.
33. Horbett TA, Brash JL. Proteins at interfaces: Current issues and future prospects. Washington: American Chemical Society 1987.
34. Anik ST, Hawang JY. Adsorption of D-Nal(2)6LHRH, a deccapeptide, onto a glass and other surface. Int J Pharm 1983; 16: 185-90.
35. Chaturvedi G. A report on stability of polypeptides and proteins. Ph.D Thesis, Birla Institute of Technology and Sciences University, Rajasthan, India, August 2009.
36. Geiger T, Clarkes S. Deamidation, isomerization and recemization at asparaginul and aspertile residues in peptide: Succinimide-linked reactions that contribute to protein degradation. J Biol Chem 1987; 262: 785-94.
37. Fisher BV, Porter PB. Stability of bovine insulin. J Pharm Pharmacol 1981; 33: 203-06
38. Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine: Nanotechnology, Biology, and Medicine 2006; 2: 53-65.
39. Nguyen TH. Oxidation degradation of protein pharmaceuticals: In formulation and delivery of protein and peptides. Washington: American Chemical Society 1994: pp. 59-71.
40. Savige WE, Fontana A. Oxidation of tryptophan to oxidolylalanine by sulphoxide- hydrochloric acid: Selective modification of tryptophan containing peptides. Int J Peptide Protein Res 1980; 15: 285-97.
41. Browning J. Disulfide scrambling of IL-II: HPLC resolution of the three possible isomers. Anal Biochem 1986: 155: 123.
42. Hanson MA, Rouan SKE. Introduction to formulation of protein pharmaceuticals: In pharmaceutical biotechnology. Stability of protein pharmaceuticals. Part B: In vivo pathway of degradation and strategies for protein stabilization. New York: Plenum Press 1992: pp. 209-13.
43. Lougheed WD, Woulfe-Flanagan H, Clement JR, Albisser AM. Insulin aggregation in artificial delivery systems. Diabetologia 1980; 19: 1-9.
44. Goldstein G, Audhya T. Stabilized aqueous formulation of thymopentin. US 5140010, 1992.
45. Hwang-Felgner J, Jones RE, Maher JF. Gamma interferon formulation. US 5151265, 1992.
46. Nguyenth TH, Ward C. Stability characterization and formulation development of alteplase, a recombinant tissue plasminogen active tor: In pharmaceutical biotechnology. Stability and characterization of proteins and peptide drugs: New York: Case histories 1993; 91-113.
47. Cleland JL, Powell MF, Shire SJ. The development of stable protein formulations-a close look at protein agreegation, deamidation and oxidation. Crit Rev Ther Drug Carr Syst 1993; 10: 310-15.
48. Schein CH. Solubility as a function of protein structure and solvent components. Biotechnolog 1990; 8: 308-17.
49. Arakawa T, Kita Y, Carpenter JF. Protein solvent interaction in pharmaceutical formulations. Pharm Res 1991; 8: 285-91.
50. Kwan HKH. Biological stable interferon composition comprising thiommerosal. US 4847079, 1989.
51. Zudiema J, Kadir F, Titulaer HAC, Oussoren C. Release and absorption rates of intramuscularly and subcutaneously injected pharmaceuticals. Int J Pharm 1994; 105: 189-207.
52. Banga AK. Therapeutic Peptides and Proteins. 2nd ed. USA: CRC Press 2005.
53. Marty JJ, Oppenheim RC, Speiser P. Nanoparticles in colloidal drug delivery system. Pharm Acta Helv. 1978; 53:17-23.
54. Tice TR, Tabibi ES. Parenteral drug delivery: Injectables: In treatise on controlled drug delivery. New York: Marcel Dekker Inc 1992: pp. 315-30.
55. Langer R. Polymer-controlled drug delivery system. Accounts Chem Res 1993; 26: 537-42.
56. Hsieh DST, Chiang CC, Desai DS. Controlled release of macromolecules from silicone elastomer. Pharm Tech 1985; 9: 39-49.
57. Ficek BJ, Peppas NA. Novel preparation of poly-vinyl alcohol microparticles without crosslinking agents for controlled drug delivery of proteins. J Controlled Rel 1993; 27: 259-64.
58. Brown L, Munoz C, Siemer L. Controlled release of insulin from polymer matrices: Control of diabetes in rats. Diabetes 1986; 35: 692-95.
59. Heller J. Polymers for controlled parenteral delivery of peptides and proteins. Adv Drug Del Rev 1993; 10: 163-204.
60. Artursson P, Edman P, Laakso T, Sojholm I. Characterization of polyacryl starch microparticles as carrier for protein and drugs. J Pharm Sci 1984; 73: 1507-13.
61. Sanders LM, McRae G, Vitale K. Design and performance of controlled release biodegradable delivery system of nafarelin: An overview. J Pharm Sci 1989; 78: 888-90.
62. Tabata Y, Gupta S, Langer R. Controlled delivery systems for proteins using poly-anhydride microsphers. Pharm Res 1993; 10: 487-96.
63. Weiner AL. Lipid-based vehicles for peptide and protein drugs: Part II: Manufacturing variables. Biopharm 1990; 3: 16-21.
64. Mariette B, Coudane J, Vert M. Release of the GRF29NH (2) analog of human GRF29NH (2) from a PLA/GA matrix. J Controlled Rel 1993; 24: 237-46.
65. Hlodan R, Pain RH. Tumour necrosis factor is in equilibrium with a trimeric molten globule at low pH. FEBS Lett 1994; 343: 256-60.
66. Engel A, Bendas G, Wilhelm F. Freeze drying of liposomes with free and membrane bound cyroprotectants-the background of protection and damaging processes. Int J Pharm 1994; 107: 99-110.
67. Niwa T, Takeuchi H, Hino T. In-vitro drug release behaviour of D,L-Lactide/Glycolide copolymer (PLGA) nanospheres with nafarelin acetate prepared by a novel spontaneous emulsification solvent diffusion method. J Pharm Sci 1994; 83:727-32.
68. Nellore RV, Pande PG, Young D, Bhagat HR. Evaluation of biodegradable microspheres as vaccine adjuvent for hepatitis-B surface antigen. J Parent Sci Tech 1992; 46: 176-80.
69. Kwok KK, Groves MJ, Burgess DJ. Production of 5-15 μm diameter alginate-polylisine microcapsules by an air-automization technique. Pharm Res 1992; 8: 341-44.
70. Langer R. Biomaterials in controlled drug delivery: New preservatives from biotechnological advances. Pharm Techn 1989; 13: 18-30.
71. Leichter SB, Schreiner ME, Reynolds LR, Bolick T. Long term follow up of diabetic patients using insulin infusion pumps: consideration for future clinical application. Arch Intern Med 1985; 145: 1409-12.
72. Kim SW, Jacobs HS. Self-regulated insulin delivery-artificial pancreas. Drug Dev Ind Pharm 1994; 20: 575-80.
73. Lee VHL, Dodda-Kashi S, Grass GM, Rubas W. Oral route of peptide and protein drug delivery: In petide and protein drug delivery. New York: Marcel Dekker 1991: pp. 691-738.
74. Yuasa H, Amidon GL, Fleisher D. Peptide carrier mediated transport in intestinal brush border membrane vesicles of rats and rabbits: Cephradine uptake and inhibition. Pharm Res 1993; 10: 400-04.
75. Lee VHL. Oral route of peptide and protein drug delivery. Biopharm 1992; 5: 39-50.
76. Bohner V, Langguth P, Biber J, Merkle HP. Intestinal mucosal transport and metabolism of pentapeptides. Proceeding International Symposium Controlled Release Bioactive Materials. Controlled release Society, Darmstadt, February, 895-96, 1994.
77. Swain S, Behera U, Beg S, et al. Design and characterization of enteric-coated controlled release mucoadhesive microcapsules of Rabeprazole sodium. Drug Dev Ind Pharm 2012; Early Online: 1-13 (Article in press).
78. LueBen H, Lehr CM, Rentel CO. Bioadhesive polymer for the peroral delivery of peptide drugs. J Controlled Rel 1993; 29: 329-38.
79. Swain SK, Beg S, Singh A. Ch. Patro N, Rao MEB. Advanced techniques for penetration enhancement in transdermal drug delivery system. Curr Drug Deliv 2011; 8: 256-73.
80. Singh J, Roberts MS. Transdermal delivery of drugs by iontophoresis: A review. Drug Design Del 1989; 4: 1-12
81. Zhou XH. Overcoming enzymatic and absorption barrier to nonparenteral administered protein and peptide drugs. J Controlled Rel 1994; 29: 239-52.
82. Reddy IK, Banga AK. Biotechnology drug delivery: Oral Vs alternate routes. Pharma Times 1993; 59: 92-98.
83. Lee VHL, Yamamoto A, Compela UB. Mucosal penetration enhancer for facilitation of peptide and protein durg absorption. Crit Rev Ther Drug Carr Syst 1991; 8: 91-192.
84. Lee VHL. Protease inhibitors and penetration enhancers as approaches to modify peptide absorption. J. Controlled Rel 1990; 13: 213-23.
85. Wearley LL. Recent progress in protein and peptide delivery by noninvasive routes. Crit Rev Ther Drug Carri Syst 1991; 8: 331-94.
86. Pontiroli AE, Calderara A, Pozza G. Internasal drug deliveru: Potential advantages and limitations from a clinical pharmacokinetic prospective. Cli Pharmacokinet 1989; 17: 299-307.
87. Stephen P, Cape JA, Villa ETS, Huang Tzung-Horng Y, John F, Carpenter, Robert ES. Preparation of active proteins, vaccines and pharmaceuticals as fine powders using supercritical or near-critical fluids. Pharm Res 2008; 25: 1967-90.
88. Cipolla D, Gonda I, Shire SJ. Characterization of aerosols of human recombinant deoxyribonuclease-i (rhDNase) generated by jet nebulizers. Pharm Res 1998; 11: 1239-42.
89. Niven RW, Lotto FD, Ip AY, Cribbs JM. Pulmonary delivery of powders and solutions containing recombinant human granulocyte colony-stimulating factor (rhG-CSF) to the rabbit. Pharm Res 1994; 11: 1101-09.
90. Adjei A, Gupta P. Pulmonary delivery of therapeutic peptides and proteins. J Controlled Rel 1994; 29: 361-73.
91. Nishihata T, Rytting JH, Kamada A. Enhancement of rectal absorption of insulin using salicylates in dogs. J Pharm Pharmacol 1983; 35: 148-51.
92. Buclin T, Randin JP, Jacquet AF. The effect of rectal and nasal administration of salmon calcitonin in normal subjects. Calcif Tissue Int 1987; 41: 252-58.
93. Nozaki Y, Kakumoto M, Ohta M. A new transmucosal therapeutic system-overview of formulation development and invitro/invivo clinical performance. Drug Dev Ind Pharm 1993; 19: 1755-1808.
94. Chou GCY, Shen ZF, Zheng YQ, Chen YJ. Enhancement of systemic delivery of peptide drug via ocular route with surfactants. Drug Dev Res 1992; 27: 177-83.
95. Chou GCY, Shen ZF, Li Byron HP. Effects of permeation enhancers bl-9 and brij-78 on absorption of four peptide eyedrops in rabbits. Acta Pharmacologica Sinica 1992; 13: 201-05.
96. Chou GCY, Chang CY. Treatment of hypoglycemia with glucagon eye drops. J Ocular Pharmacol 1988; 4: 179-86.
97. Chou GCY, Shen ZF, Zheng YQ. Systemic absorption of oxytocin and vasopressin through eyes in rabbits. J Ocular Pharmacol. 1991; 7: 351-58.
98. Hoppenreiji VPT, Pels E, Vrensen GFJM et al. Effects of human epidermal growth factors on endothelial wound hilling of human corneas. Invest. Opthalmol Visual Sci 1992; 33: 1946-57.
99. Grant MB, Manes RM, Fitzgerald C. Insulin-like growth factor-1 acts as an angiogenic agent in rabbit cornea and retina: Comparative study with basic fibroblast growth factor. Diabetologia.1993; 36: 282-91.
100. Almegerd B, Andersson SE. Vascular effect of calcitonin generelated peptide (CGRP) and colecystokinin (CCK) in the monkey eye. J Ocular Pharmacol 1993; 9: 77-84.
101. Shirwaiker A, Jacob S, Srinivasan KK. Stability of protein in aqueous solution and solid state. Indian J Pharm Sci 2006; 68: 154-63.
102. Jorgensen L, Hostrup S, Moeller EH, Grohganz H. Recent trends in stabilizing peptides and proteins in pharmaceutical formulationconsideration in the choice of excipients. Expert Opin Drug Deliv 2009; 6: 1219-30.
103. Mahato RI, Narang AS, Thoma L, Miller DD. Emarging trends in oral delivery of peptide and protein drugs. Critical ReviewTM in Therapeutic Drug Carrier System 2003; 20: 153-214.
104. Shaji J, Patole V. Protein and peptide drug delivery. Oral Approach 2008; 70: 269-77.
105. Chaturyedula A, Joshi DP, Anderson D. In-vivo inotophoretic delivery and pharmacokinetics of salmon calcitonin. Int J Pharm 2005; 297: 190-96.
106. Green PG. Iontophoretic delivery of peptide drugs. J Controlled Rel 1996; 41: 33-48.
107. Kumar S, Char H, Patel S. In vitro transdermal inotophoretic delivery of growth hormone releasing factor GRF (1-44) in hairless guinea pigs. J Controlled Rel 1992; 18: 213-20.
108. Ruland A, Kreuter J, Rytting JH. Transdermal delivery of the tetrapeptide hisetal melanotropin. I. Effect of various penetration enhancers: in vitro study across hairless mouse skin. Int J Pharm 1994; 101: 57-61.
109. Khan A, Yasir M, Asif M et al. Iontophoretic drug delivery: History and application. J Appli Pharm Sci 2011; 1: 11-22.
110. Park EJ, Dodds J, Smith NB. Dose comparison of ultrasonic transdermal insulin delivery to subcutaneous insulin injection. Int J Nanomed 2008; 3: 335-41.
111. Sumeet K, Rastogi, Singh J. Transepidermal transport enhancement of insulin by lipid extraction and iontophoresis. Pharm Res 2003; 19: 427-33.
112. Egbaria K, Ramachandran C, Kiitayanond D, Weiner N. Topical delivery of liposomally encapsulated interferon evaluated by in vitro diffusion studies. Antimicro Agen Chemother 1990; 34: 107-10.
113. Fu Lu M Y, Lee D, Rao GS. Percutanious absorption enhancement of leuprolide. Pharm Res 1992; 9: 1575-79.
114. Dhote V, Bhatnagar P, Mishra PK et al. Iontophoresis: A potential emergence of a transdermal drug delivery system. Sci Pharmaceut 2012; 80: 1-28.
115. Rawat S, Vengurlekar S, Rakesh B, Jain S, Srikarti G. Transdermal delivery by iontophoresis. Ind Pharm Sci 2008; 70: 5-10.
116. Cullander C, Guy RH. Routes of delivery: Case studies: Transdermal delivery of peptides and proteins. Adv Drug Deli Rev 1992; 8: 291-329.
117. Juul-Mortensen C, Kobenhaven V. Stabilized pharmaceutical peptide composition. US8114959 B292, 2012.
118. Engelund DK, Pedersen T B, Bonde C. Stable pharmaceutical composition. US0084605 A1, 2006.
119. DeFelippis MR, Dobbins MA, Sharkns AD. Polypeptide Composition with improved stability. US7022674B2, 2006.
120. Knudsen LB, Hansen KT, Engelund DK. Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia. US0287221A1, 2006.
121. Takruri H. Method for the stabilization of methionine-containing polypeptides. US5272 135, 1993.
122. Fabian S, Dirk F. Stabilization of pharmaceutical protein formulations with small peptides. US7141544, 2006.
123. Fink JM, Larsen SM, Jensen SB, Engelund DK. Stable formulation of modified GLP-1. US2003/0119734A1, 2003.
124. Kaarsholm MC. Stabilized Aqueous Peptide Solutions. US 6384016B1, 2002.
125. Furuya H, Morita H, Tahatsu Y. Method for stabilizing peptides and freeze-dried medicainal compositions containing peptides obtained by using the method. US6274553 B1, 2001.
126. Gibson TD, Pierce BL, Wegster JI. Stabilization of protein in solution. US6133229, 2000.
127. Lee LS. Stabilized monomeric protein compositions. US5917021, 1999.
128. Deutsch EA, Geodetmans WT, Miller KM, Brodack JW. Stabilizers to prevent autoradiolysis of radiolabeled peptide and proteins. US 5384113, 1995.
129. Fukuta M, Itho H. Stabilized pharmaceutical preparations. US6187340B1, 2001.
130. Miller KM, Fourniere LL. Stabilization of proteins and peptides for radiopharmaceutical use. US6174513B1, 2001.
131. Altman E. Stabilized bioactive peptides and methods of identification, synthesis and use. US6818611B1, 2004.
132. Jaber A. Method of stabilizing proteins. US7858082B2, 2010.